Single-dose Decline Explorer
Explore when one modelled dose falls below a chosen percentage of its sampled peak.
This is a relative curve comparison, not a drug-free date, detection window, or treatment-switching plan. The model includes one dose only, with no prior accumulation. Defaults are example inputs.
An input to the model, not a recommended dose.
A mathematical comparison only. The example 5% is not a clinical cutoff or a percentage of drug remaining in the body.
Model horizon: 16 weeks from one dose at time zero. Unavailable models are excluded; compound reference entries remain available.
Model details: 5-Amino-1MQ · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 12 hours
- Absorption half-life assumed
- 3 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Human route/formulation, systemic exposure, absorption and terminal kinetics were not established by the reviewed source. Cell permeability cannot supply oral bioavailability.
- Neelakantan et al. 2018: NNMT inhibitors and diet-induced obesity
Cell permeability and mouse efficacy experiments do not provide matched human systemic Cmax, absorption or elimination parameters.
5-amino-1mq-relative-timing-2026-10 · version 1
Sampled model decline
Relative timing · not blood concentrations
- Highest sampled model level
- 50.0 relative units at 8.00 hours
- Selected relative threshold (5%)
- 2.50 relative units
Post-peak threshold comparison
Between 2.67 days and 2.78 days after the model dose
This brackets the final sampled downward crossing. Every later sample stays below the threshold through 112.00 days. It is not a measured biological crossing.
Curve height depends on model parameters. Relative units describe a timing model, not blood concentrations. The engine samples time and truncates small tails. Earlier doses, metabolites, assay sensitivity, and individual physiology are not evaluated here.
Five half-lives leaves 3.125% in an ideal single-exponential decay calculation; it does not mean zero drug or establish a safe medical interval. Product-specific decisions require the applicable prescribing information and clinical assessment. For example, the Ozempic prescribing information sets its own circumstances for discontinuation. This explorer does not calculate such instructions.
About this tool
Explore when one modelled dose falls below a chosen percentage of its highest sampled concentration. The tool reports a sampled crossing interval within a 16-week horizon. The percentage is a mathematical comparison, not a clinical cutoff or a measure of drug remaining in the body; no drug-free, treatment-switching, or testing date is calculated.
How to use it
- 1 Select an available compound model. Entries whose models are under review remain available as compound references.
- 2 Enter a positive model dose. Default values are examples, not dose recommendations.
- 3 Choose a threshold greater than 0% and less than 100% of the modelled peak.
- 4 Read the post-peak crossing bracket, or the explanation that the horizon or numerical resolution cannot resolve it. Earlier doses are not included.
Frequently asked questions
Does 5% mean only 5% of the drug remains?
No. It means 5% of this single-dose curve's highest sampled concentration. It is not a measured body burden, an assay detection limit, or a clinical decision threshold.
Why might no crossing time be shown?
The curve may not complete its decline within the sampled horizon, or the requested threshold may lie below the model's numerical resolution. A model zero is not proof that drug is absent.
Can I use this to plan treatment changes, PCT, or drug testing?
No. The model omits prior accumulation, metabolites, assay sensitivity, and individual physiology. Such decisions require the relevant product information and clinical assessment rather than this relative curve comparison.
Educational use only — not medical advice.